|Bid||5.83 x 3000|
|Ask||5.85 x 4000|
|Day's Range||5.83 - 5.85|
|52 Week Range||1.10 - 5.85|
|Beta (3Y Monthly)||4.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 15, 2018 - May 21, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.88|
NEW YORK, March 20, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Civitas Solutions, Inc.,.
WILMINGTON, Del., March 18, 2019 -- Rigrodsky & Long, P.A.: Do you own shares of Immune Design Corp. (NASDAQ GM: IMDZ)?Did you purchase any of your shares prior to.
NEW YORK , March 5, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
BALA CYNWYD, PA / ACCESSWIRE / February 22, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Immune Design Corp. ("Immune ...
HENDERSON, NV / ACCESSWIRE / February 22, 2019 / Below are several healthcare companies in the news leading the sector recently. A company in the sector that has not had news recently but according to ...
NEW YORK, Feb. 22, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Immune Design Corp. (NASDAQ: IMDZ) on behalf of.
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 21.) Eli Lilly And Co (NYSE: LLY ) Gossamer ...
Dow Jones component Merck, in an effort to bolster its vaccine offerings, will spend $300 million to buy Immune Design. Immune Design stock flew more than 300% as Merck rose a fraction.
NEW YORK , Feb. 21, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Immune Design Corp. (NASDAQ: IMDZ) and its board of directors for breach of fiduciary duty concerning ...
NEW YORK , Feb. 21, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Immune Design Corp. ("IMDZ" ...
NEW YORK, Feb. 21, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Immune Design Corp. (“Immune Design”.
Biotech M&A is on a roll in 2019, with a couple of multi-billion dollar deals announced already, including Bristol-Myers Squibb Co (NYSE: BMY )'s proposed buy of Celgene Corporation (NASDAQ: CELG ) and ...
CORAL GABLES, FL / ACCESSWIRE / February 21, 2019 / The recent success of the healthcare stock market can be attributed to the fact that companies in the healthcare industry are looking into new innovative approaches and technologies to better improve their offerings for consumers. Whereas cannabis was previously condemned as a harmful substance, medical experts have released studies showing that medicinal cannabis can be used to reduce inflammation caused by inflammatory diseases, as well as help patients suffering from acute anxiety, and countless other uses. In addition to the medical field shifting towards accepting medicinal cannabis, the healthcare sector, overall, has placed more emphasis on investing in the patient and their quality of life.
SAN DIEGO , Feb. 21, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immune Design Corp. (NASDAQ: IMDZ) ("Immune ...
Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs. Merck will pay $5.85 in cash for each share of Immune ...
The direct benefit for Immune Design Corp. (NASDAQ:IMDZ), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
In the 26 naïve and relapsed/refractory patients in the randomized trial, the data continue to support the clinical activity of G100, with overall response rates of 46% and 23% in patients receiving a G100 regimen that includes low-dose radiation, with or without pembrolizumab, respectively. Also, disease control was shown in 92% and 85% of patients treated with the G100 regimen with or without pembrolizumab, respectively. In addition, responses appeared to be durable, with overall progression free survival at 11.1 or 7.4 months in patients treated with the G100 regimen with or without pembrolizumab, respectively.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today.